Articles

TTIP – bringing benefits to patients or big pharma?

22nd September 2014

TTIP – bringing benefits to patients or big pharma?Emma Woodford

Emma Woodford, EPHA Interim Secretary General, explains the organisation's stance on the Transatlantic Trade and Investment Partnership (TIPP) and the wider implications for health once negotiations close towards the end... Read more

Real world cost effectiveness: lessons from the MS risk sharing scheme

19th September 2014

Real world cost effectiveness: lessons from the MS risk sharing schemeLeela Barham

Real world cost effectiveness data is in high demand, but how easy is it to find and assess in practice? Leela Barham investigates the pros and cons through an examination... Read more

How can UK pay for Sovaldi? Health bonds, says pharma leader

18th September 2014

How can UK pay for Sovaldi?  Health bonds, says pharma leaderAndrew McConaghie

The problem of highly effective but high priced and 'unaffordable' medicines such as Sovaldi needs to be addressed in the UK - and could be solved by adopting creative solutions.That... Read more

Tunnah’s musings: Taking the medical congress beyond the medic

18th September 2014

Tunnah’s musings: Taking the medical congress beyond the medicPaul Tunnah

In this month's musings, Paul Tunnah explores the continued interest in medical congresses beyond the physical event and outlines how pharmaphorum is looking to facilitate sharing virtual perspectives on them... Read more

News

TauRx hits milestone in mild Alzheimer's trial

22nd September 2014

TauRx hits milestone in mild Alzheimer's trialStaff reporter

Singapore-based TauRx has completed enrolment in a second pivotal trial of its Alzheimer's disease (AD) candidate LMTX, setting it on course for a data read-out in early 2016.TauRx is bucking... Read more

Merck to acquire Sigma-Aldrich for $17 billion

22nd September 2014

Merck to acquire Sigma-Aldrich for $17 billionAndrew McConaghie

German pharma company Merck is to pay $17 billion to acquire Sigma-Aldrich, a specialist in chemicals, kits and services used in life sciences research.Headquartered in Damstadt, Merck is a diversified... Read more

Positive results for Alexion's latest ultra rare treatment

22nd September 2014

Positive results for Alexion's latest ultra rare treatmentLinda Banks

Alexion Pharmaceuticals has announced promising data from the extension phases of two phase II studies of asfotase alfa, an investigational enzyme replacement therapy, in paediatric patients with ultra-rare disease hypophosphatasia... Read more

UN steps up response as Ebola death toll mounts

22nd September 2014

UN steps up response as Ebola death toll mountsAndrew McConaghie

The United Nations has taken the unprecedented step of creating a multi-agency mission to fight the Ebola outbreak in West Africa.Nearly six months after the first case of Ebola in... Read more

Audio & Video

Live webinar: Is pharma brand marketing …

Kantar Health webinar


While pharma observers speculate on the death of outdated drug discovery and sales models, some critical wounds to brand marketing have been... View more

Tweetchat: Managing diabetes in the real…

Atlantis Healthcare diabetes Tweetchat


Atlantis Healthcare is working with pharmaphorum to conduct a Tweetchat on the real world challenges patients face in managing... View more

Patient Opinion Leaders: Andrew Schorr

 

As a cancer survivor and passionate patient advocate, Andrew Schorr typifies the concept of a Patient Opinion Leader (POL). He is a contributor to the... View more

View the recorded webinar - The future o…

WEBINAR COVER smaller


The global pharmaceutical market passes a significant milestone in 2014: reaching one trillion US dollars in total value. IMS Health... View more

White Papers

Diabetes in France

Diabetes in FranceJanet Gunner

Analysis of open social media in relation to a particular disease area can provide useful intelligence on how different treatments and pharmaceutical companies are perceived, by both doctors and patients,... View info

Diabetes in Germany

Diabetes in GermanyJanet Gunner

Analysis of open social media in relation to a particular disease area can provide useful intelligence on how different treatments and pharmaceutical companies are perceived, by both doctors and patients,... View info

Connected data and the use of smartphone…

Connected data and the use of smartphone enabled apps in market researchPaul Mannu

Rapid growth in smartphone usage offers healthcare researchers a useful tool to gain better understanding of how patients and healthcare professionals actually behave on a daily basis. Inaccuracies can arise... View info

Diabetes in the UK

Diabetes in the UKJanet Gunner

Analysis of open social media in relation to a particular disease area can provide useful intelligence on how different treatments and pharmaceutical companies are perceived, by both doctors and patients,... View info

Further News & Articles

Pharma cheered by Scotland's 'no' vote

The decision by Scotland's voters to remain in the United Kingdom has been welcomed by investors and businesses ... Read more

News

GSK China guilty of bribery

The Changsha Intermediate People's Court in Hunan Province, China, has ruled that GlaxoSmithKline China Inves... Read more

News

European Commission 'has limited power to tackle drug pricing'

A debate in the European Parliament on access to life-saving medicines has heard that while there is widespre... Read more

News

Cubist extends superbug R&D to Europe

Recognising that antibiotic resistance is a growing public health issue worldwide, the global leader in antib... Read more

News

NICE 'office for innovation' would smooth path of new drugs

NICE has just unveiled far-reaching proposals for a 'new approach' to managing the entry of drugs onto the NHS.<... Read more

News

Gilead drug fails in pancreatic cancer

A novel cancer treatment from Gilead has failed in phase 2 trials in advanced pancreatic cancer.
<... Read more

News